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Introduction
The development and severity of the acute respiratory distress 
syndrome (ARDS) observed in patients with coronavirus disease 
2019 (COVID-19) is a potentially fatal condition and, at the same 
time, a determining factor in the prognosis of it pathology [1]. In 
this sense, a study developed by Quesada-Gómez and colleagues 
 
reported that approximately 20% of hospitalized patients [both 
in the intensive care unit (ICU) and not admitted to the ICU] with 
COVID-19 developed ARDS and, despite recent improvements 
in the strategies of mechanical ventilation and supportive care, 
around 65% of patients with ARDS died [2]. ARDS is a fundamental 
component of the pathophysiology of this disease, whereby patients 
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The leading cause of complications or death from COVID-19 is due to the development 
of acute respiratory distress syndrome (ARDS). This syndrome is characterized by 
exacerbated inflammation, mainly at the pulmonary level, and an over-activation of 
the renin-angiotensin-aldosterone system (RAAS), usually culminating in death or 
permanent respiratory sequelae in the SARS-CoV-2 infected patients. In this sense, 
it has been proposed that vitamin D exerts numerous immunomodulatory effects by 
acting on various types of immune and epithelial cells, as well as being able to stimulate 
the protective arm (ACE2/Ang-(1-7)) and inhibit the harmful arm (ACE/Ang-II) of the 
RAAS. Therefore, some of the main mechanisms underlying these effects mediated by 
vitamin D and its receptors are discussed in the present review. The analysis of these 
mechanisms would positively influence the prevention and treatment of ARDS, thus 
preventing the progression of the disease and improving the prognosis of the patients.
Abbreviations: ARDS: Acute Respiratory Distress Syndrome; ICU: Intensive Care 
Unit; RAAS: Renin-Angiotensin-Aldosterone System; VD: Vitamin D; VDR: Vitamin 
D Receptors; LPS: Lipopolysaccharides; ACE: Angiotensin Converting Enzyme; ERK: 
Extracellular Signal-Regulated Kinases
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with severe COVID-19 develop multi-organ dysfunction. The onset 
of ARDS is usually rapid and progressive, developing approximately 
nine days after the onset of severe COVID-19 [3] infection. The 
disease has been challenging to manage in terms of high morbidity 
and mortality, high costs and long periods of hospitalization in 
intensive care. Therefore, early treatment is essential to control 
the progression of the infection and improve the prognosis of 
patients with ARDS [4,5]. ARDS develops as a consequence of an 
exaggerated or uncontrolled inflammatory response known as a 
“cytokine storm”, resulting from the release of large concentrations 
of these proteins (IFN-α, IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-33, 
TNF-α, TGF-β, CCL2, CCL3, CCL5, CXCL8, CXCL9, CXCL10, etc.) pro-
inflammatory by immune effector cells during SARS-CoV-2 [6] 
infection. Furthermore, the activation and excessive recruitment 
of neutrophils into the alveolar interstitium with disruption of the 
endothelial-epithelial barrier and the consequent alveolar damage 
exacerbates the pathogenesis of ARDS [7]. Of particular interest, 
the data obtained to date from patients infected with SARS-CoV-2 
confirmed that those who required admission to the ICU had higher 
concentrations of GCSF, IP10, MCP1, MIP1A, and TNF-α than those 
that did not require it, which reaffirms the fact that the intensity 
of the cytokine storm is usually associated with the severity of the 
disease [8]. 
Currently, multiple therapeutic behaviors are used -some 
empirically based and others based on limited evidence- with 
varying efficiencies for ARDS management, mainly associated with 
supportive care such as mechanical ventilation and hemodynamic 
management [9]. Of particular interest, it is known that vitamin D 
(VD) and its receptors (VDR) are present in all living beings that 
are part of the animal kingdom, playing a fundamental role in the 
maintenance of bone health and phospho-calcium metabolism. 
However, the fact that VD precursors have also been found in 
invertebrate organisms such as krill and phytoplankton [10] 
highlights their importance in regulating numerous additional 
physiological and homeostatic processes, such as controlling 
inflammation and oxidative stress [11,12]. Therefore, VD could 
play a leading role in the prevention and treatment of oxidative and 
inflammatory diseases such as COVID-19 by attenuating several 
of the underlying mechanisms involved in the pathophysiology of 
this viral infection. VD deficiency is associated with an increased 
risk of respiratory infection [13-16]. Likewise, a recent meta-
analysis involving around 10,000 individuals from 25 health 
centers concluded that VD supplementation reduced the risk of 
upper respiratory tract infections by approximately 19%, with 
patients being severely deficient in VD who experienced the 
greatest benefit [17]. Additionally, VD has demonstrated, in in 
vitro models, its ability to inhibit the production and release of 
cytokines (IFN-α, IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-33, and TNF-α) 
and chemokines (CCL2, CCL3, CCL5, CXCL8, CXCL9, and CXCL10) 
involved in the development and progression of ARDS [18]. Indeed, 
it has been reported that VD and VDR signaling may provide some 
beneficial effects in ARDS through multiple mechanisms, including 
attenuation of the cytokine and chemokine storm [19], regulation 
of the renin-angiotensin-aldosterone system (RAAS) [20] and the 
maintenance of the integrity of the pulmonary epithelial barrier 
[21], among other aspects, which will be addressed in this review.
Role of Vitamin D in Immuno-Modulation and its 
Potential Efficacy during COVID-19
More than a century ago (1849), the British physician C.J.B. 
Williams reported that in a study of 234 tuberculosis patients, 
206 of them showed a “marked and unequivocal improvement” 
after treatment with cod liver oil (rich in VD) [22]. Since then, 
various VD functions related to the regulation of numerous cellular 
processes have been investigated, concluding that its deficiency 
is potentially involved in the development of multiple diseases 
[23]. Additionally, since the discovery of the presence of VDR in a 
wide variety of cells of the immune system, countless studies on 
the immunomodulatory effect of RV, that is, its ability to stimulate 
(e.g. to accelerate the elimination of a pathogen) or inhibit (e.g. 
to attenuate uncontrolled inflammation) the immune response 
according to specific circumstances. In detail, these studies revealed 
that VD would modulate the activity of various immune cells, 
including monocytes, macrophages, lymphocytes and epithelial 
cells [24]. In the case of macrophages, it has been observed that low 
serum concentrations of VD in patients with rickets correlate with 
a decrease in their phagocytic activity, which could be reversed by 
supplementation with 1,25-dihydroxyvitamin D3 (1,25-(OH )2D3), 
or also called calcitriol, the active form of VD [25]. For its part, it 
has been reported that the antimicrobial activity of macrophages 
increases in the presence of 25-hydroxyvitamin D3 (25-(OH)D3) 
after stimulation with antigen ligands. 
This is because the activation of different macrophage 
receptors (TLR-2, TLR-4, among others) by foreign agents leads 
to an increased expression of VDR and of the CYP27B enzyme, 
which increases both the conversion of 25-(OH)D3 into its 
active form 1,25- (OH)2D3 mediated by the CYP27B enzyme, as 
well as from the expression of antimicrobial peptides such as 
cathelicidin and β2-defensin through VDR [26,27]. Both peptides 
contribute to hosting defenses by stimulating the expression of 
antiviral cytokines and chemokines involved in the recruitment of 
monocytes/macrophages, neutrophils and T lymphocytes, among 
other immune cells [28]. Another mechanism by which VD can 
promote innate immune function through antimicrobial peptides is 
closely linked to improving phagocytosis through the induction of 
autophagy [29]. SARS-CoV-2 uses blocking autophagy to accelerate 
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its replication and infectivity. By achieving this, the virus induces 
the expression of the Skp2 protein, which plays a central role in the 
viral replication mechanism during COVID-19 disease and, in turn, 
inactivates Beclin 1, a component of the autophagic process [30,31]. 
In parallel, 1,25-(OH)2D3 also stimulates the production of Klotho, 
known to attenuate multi-organ aging and increase longevity, 
which also promotes autophagy through the maintenance of 
adequate cellular levels of Beclin 1 [32]. Concerning B lymphocytes, 
1,25-(OH)2D3 has been shown to play an important role in the 
homeostasis of these cells through the inhibition of proliferation and 
the induction of apoptosis in activated B cells. Likewise, 1,25-(OH) 
2D3 inhibits the differentiation of B lymphocytes to plasma cells 
and memory B cells. These mechanisms can prevent or attenuate 
the pathogenesis of diseases involving B lymphocytes [33]. About 
T lymphocytes, the biologically active 1,25-(OH)2D3 is capable of 
modifying the immune response, shifting it from a T helper 1 (pro-
inflammatory) profile to a T helper 2 (anti-inflammatory) profile. 
Additionally, 1,25-(OH)2D3 directly affects the differentiation of 
regulatory T cells and modulates the functions of dendritic cells 
[34]. As for the respiratory epithelium cells, they express enzymes 
capable of converting the precursor 25-(OH)D3 into its active form 
1,25-(OH)2D3. 
Therefore, these cells constitute an important source of 
1,25-(OH)2D3 that induces the expression of cathelicidin and 
CD14 by cells of the immune system [35]. Furthermore, type II 
cuboidal alveolar cells of the lung also express VDR to a large 
extent. Thus, VDR overexpression exerts a pulmonary anti-
inflammatory effect [36,37]. VDR knockout mice experienced more 
severe acute lung injury than wild-type mice after being treated 
with lipopolysaccharides (LPS) [38]. Calcitriol/VDR signaling can 
also protect against acute lung injury by modulating genes that 
regulate the expression of occluding, a protein responsible for the 
maintenance of alveolar epithelial tight junctions, avoiding the 
increased permeability of the epithelial-alveolar barrier stimulated 
by the inflammatory answer. Therefore, 1,25(OH) 2D is essential 
to maintain the structure and function of the epithelial barriers of 
the lung, among other tissues [21]. In this sense, the mechanisms 
described could represent potential immunomodulatory pathways 
against the SARS-CoV-2 virus induced by VD, outlined in Figure 1.
Figure 1: Potential immuno-modulating mechanisms of vitamin D at the endothelial-alveolar barrier level against infection by 
the SARS-CoV-2 virus. Solid arrows indicate “stimulation”, and broken arrows indicate “inhibition.”
Role of the Renin Angiotensin System in the Pathogenesis 
of COVID-19 and its Relationship with the Protective 
Role of Vitamin D
Local or systemic inflammatory responses can activate RAAS. 
Likewise, the hyper-activation of RAAS induced by SARS-CoV-2 
together with the consequent decrease in angiotensin-converting 
enzyme 2 (ACE2), have been implicated in the pathogenesis of 
ARDS by COVID-19 [39]. Thus, angiotensin II (Ang-II) generated by 
angiotensin converting enzyme 1 (ACE) is capable of inducing lung 
injury, while ACE2 counter-regulates the effects produced by Ang-II 
by converting Ang II into Ang-(1-7), which in turn activates the Mas 
receptor to repress the STAT3 signaling pathways and extracellular 
signal-regulated kinases (ERK), acting as an anti-inflammatory 
factor. Therefore, the alteration of the balance between the levels 
of the enzymes ACE and ACE2, affect the endogenous relationship 
of Ang-II/Ang-(1-7), with elevation of Ang-II, this being a key factor 
for the development of ARDS in animal and human models [40]. 
Additionally, it is important to note that SARS-CoV-2 does not 
enter cells through coronavirus receptors such as aminopeptidase 
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N and dipeptidyl peptidase 4, but rather through the ACE239, 
[40] receptor. In this sense, approximately 83% of the cells that 
express the ACE2 receptor are a type II alveolar epithelial cell, 
which suggests that these cells can serve as a reservoir for viral 
invasion, further complicating the situation at the pulmonary level 
[41]. Interestingly, it has been observed that the expression of ACE2 
(but not that of ACE) is significantly reduced in lung tissue during 
SARS-CoV-2 [42] infection. In this way, a crucial lung protection 
mechanism is lost, and the SARS-CoV-2 infection becomes more 
lethal, with recruitment, accumulation and exaggerated activation 
of neutrophils and macrophages, increased vascular permeability 
due to the breakdown of the barrier epithelial-alveolar (with 
diffuse alveolar damage and exacerbated edema at the pulmonary 
level), which will eventually lead to ARDS. In this state, the lungs 
cannot provide enough oxygen to the blood, which is essential for 
the proper functioning of vital organs [43]. Additionally, this state 
of hyper-inflammation and the over-activation of the RAAS are 
intimately involved in the alteration of the coagulation cascade, 
which leads to a prothrombotic state, commonly observed in 
ARDS during SARS-CoV-2 infection [44,45]. Another consequence 
of COVID-19 is the potential risk of fibrosis with impaired lung 
function in recovered patients [46,47].
In this sense, there is ample evidence that 1,25(OH)2D/VDR 
signaling is a potent negative regulator of RAAS [13,19,20]. Renin 
levels are elevated in VDR knock-out mice. Chronic VD deficiency 
can induce activation of RAAS. 1,25(OH)2D can reduce renin, ACE 
and Ang-II levels, simultaneously increasing ACE2 levels during 
lipopolysaccharide-induced acute lung injury [48]. Xu and colleagues 
conducted a study on rat lung endothelial cells to determine 
whether calcitriol at concentrations of 5, 20, and 100nM affects 
lipopolysaccharide-induced acute lung injury. The results indicated 
that the higher concentration of calcitriol (100nM) significantly 
reduced the deleterious effects of lipopolysaccharides on ACE and 
ACE2 levels, suggesting an essential role for the active form of VD 
in attenuating acute lung injury. In parallel, and considering that 
the type 1 Ang-II receptor (AT1) is a downstream effector of ACE, 
the effects of lipopolysaccharides and calcitriol on its expression 
were then investigated. In line with the results described above, a 
significant increase in AT1 mRNA expression was observed in cells 
exposed to lipopolysaccharides compared to those that were not, 
while calcitriol reduced the effect of lipopolysaccharides on AT1 
mRNA levels in a dose-dependent manner. It should be noted that 
the mRNA expression of the Ang-II type 2 receptor (AT2), used as 
a control, was not significantly altered. Therefore, these results 
confirm that calcitriol can prevent lipopolysaccharide-induced 
acute lung injury in rat lung endothelial cells, at least partly due to 
ACE2/Ang-(1-7) axis activation and inhibition of the ACE/Ang-II/
AT1R axis of the RAS [49].
On the other hand, we must consider that 1,25(OH)2D also 
positively regulates ACE2; thus VD could facilitate the uptake of 
viruses in cells that express this enzyme in their membranes. This 
dual effect means that ACE2 can potentially behave both in a harmful 
and beneficial way, which generated controversies and intense 
debates related to using Ang-II antagonists in hypertensive patients 
[50]. Despite this, most experts concluded that the beneficial effects 
of ACE2 on the lungs would negate its role in the entry of the virus 
into these cells [51]. Figure 2 outlines the relationship between VD 
and RAAS in the context of COVID-19.
Figure 2: Regulation of the renin-angiotensin-aldosterone system by vitamin D and its protective effects during COVID-19. 
Solid arrows indicate “stimulation”, and broken arrows indicate “inhibition.”
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Conclusion and Perspectives
Numerous studies indicate that VD deficiency is associated 
with increased morbidity and mortality in patients with COVID-19. 
Furthermore, it has been suggested that VD supplementation would 
reduce the risk of developing ARDS in these individuals. However, 
the underlying molecular mechanisms of VD in the prevention and 
attenuation of this respiratory condition during COVID-19 are still 
not fully understood, which is crucial to develop better therapeutic 
management that allows saving the lives of patients infected with 
SARS- CoV-2. Currently, several clinical trials are being carried 
out worldwide to evaluate the effects of VD supplementation in 
patients with COVID-19, both individually and in combination with 
other active ingredients, comparing the effect of high doses versus 
standard doses. However, the available evidence does not allow VD 
supplementation as an authorized therapy in patients admitted to 
health care centers. Therefore, as a perspective, we propose the 
challenge of generating new evidence through multicenter clinical 
studies based on VD supplementation to patients with COVID-19 
and applying the knowledge of critical analysis in order to obtain 
successful results.
Authors’ Contribution
All authors contributed in the same way in the conception and 
design of the review, with a substantial contribution on the data, 
analysis and interpretation of the contents, writing and critical 
review of the article for its intellectual content.
Declaration of Conflict of Interest
The authors declare no potential conflicts of interest concerning 
the research, authorship and/or publication of this article.
Financial Support
The authors declare that they have not received financial 
support for the research, authorship and/or publication of this 
article.
References
1. Batah SS, Fabro AT (2021) Pulmonary pathology of ARDS in COVID-19: A 
pathological review for clinicians. Respir Med 176: 106239. 
2. Quesada Gomez JM, Entrenas Castillo M, Bouillon R (2020) Vitamin D 
receptor stimulation to reduce acute respiratory distress syndrome 
(ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms 
SBMB 2020_166. J Steroid Biochem Mol Biol 202(105719): 105719.
3. Li X, Ma X (2020) Acute respiratory failure in COVID-19: is it “typical” 
ARDS? Crit Care 24(1): 198. 
4. Ferguson ND, Pham T, Gong MN (2020) How severe COVID-19 infection 
is changing ARDS management. Intensive Care Med 46(12): 2184-2186. 
5. Fan E, Beitler JR, Brochard L, Calfee CS, Ferguson ND, et al. (2020) 
COVID-19-associated acute respiratory distress syndrome: is a different 
approach to management warranted? Lancet Respir Med 8(8): 816-821.
6. Lin SH, Zhao YS, Zhou DX, Zhou FC, Xu F (2020) Coronavirus disease 
2019 (COVID-19): cytokine storms, hyper-inflammatory phenotypes, 
and acute respiratory distress syndrome. Genes Dis 7(4): 520-527. 
7. Yang SC, Tsai YF, Pan YL, Hwang TL (2020) Understanding the role of 
neutrophils in acute respiratory distress syndrome. Biomed J 20: S2319-
4170.
8. Kox M, Waalders NJB, Kooistra EJ, Gerretsen J, Pickkers P (2020) Cytokine 
Levels in Critically Ill Patients With COVID-19 and Other Conditions. 
JAMA 324(15): 1565-1567.
9. Peck TJ, Hibbert KA (2019) Recent advances in the understanding and 
management of ARDS. F1000Res 8: F1000.
10. Hernigou P, Auregan JC, Dubory A (2018) Vitamin D: part I; from 
plankton and calcified skeletons (500 million years ago) to rickets. Int 
Orthop 42(9): 2273-2285. 
11. Ferder M, Inserra F, Manucha W, Ferder L (2013) The world pandemic 
of vitamin D deficiency could possibly be explained by cellular 
inflammatory response activity induced by the renin-angiotensin 
system. Am J Physiol Cell Physiol 304(11): C1027-1039. 
12. De Las Heras N, Martín Giménez VM, Ferder L, Manucha W, Lahera 
V (2020) Implications of Oxidative Stress and Potential Role of 
Mitochondrial Dysfunction in COVID-19: Therapeutic Effects of Vitamin 
D. Antioxidants (Basel) 9(9): 897.
13. Ferder L, Martín Giménez VM, Inserra F, Tajer C, Antonietti L, et al. (2020) 
Vitamin D supplementation as a rational pharmacological approach in 
the COVID-19 pandemic. Am J Physiol Lung Cell Mol Physiol 319(6): 
L941-L948.
14. Martín Giménez VM, Inserra F, Ferder L, García J, Manucha W (2021) 
Vitamin D deficiency in African Americans is associated with a high risk 
of severe disease and mortality by SARS-CoV-2. J Hum Hypertens 35(4): 
378-380.
15. Mariani J, Giménez VMM, Bergam I, Tajer C, Antonietti L, et al. (2021) 
Association Between Vitamin D Deficiency and COVID-19 Incidence, 
Complications, and Mortality in 46 Countries: An Ecological Study. 
Health Secur 19(3): 302-308.
16. Martín Giménez VM, Ferder L, Inserra F, García J, Manucha W (2020) 
Differences in RAAS/vitamin D linked to genetics and socioeconomic 
factors could explain the higher mortality rate in African Americans with 
COVID-19. Ther Adv Cardiovasc Dis 14: 1753944720977715.
17. Martineau AR, Jolliffe DA, Greenberg L, Aloia JF, Bergman P, et al. (2019) 
Vitamin D supplementation to prevent acute respiratory infections: 
individual participant data meta-analysis. Health Technol Assess 23(2): 
1-44. 
18. Bui L, Zhu Z, Hawkins S, Cortez Resendiz A, Bellon A (2021) Vitamin D 
regulation of the immune system and its implications for COVID-19: A 
mini review. SAGE Open Med 9: 20503121211014073. 
19. Martín Giménez VM, Inserra F, Tajer CD, Mariani J, Ferder L, et al. (2020) 
Lungs as target of COVID-19 infection: Protective common molecular 
mechanisms of vitamin D and melatonin as a new potential synergistic 
treatment. Life Sci 254: 117808. 
20. Giménez VMM, Sanz RL, Marón FJM, Ferder L, Manucha W (2020) Vitamin 
D-RAAS Connection: An Integrative Standpoint into Cardiovascular and 
Neuroinflammatory Disorders. Curr Protein Pept Sci 21(10): 948-954.
21. Chen H, Lu R, Zhang YG, Sun J (2018) Vitamin D Receptor Deletion Leads 
to the Destruction of Tight and Adherens Junctions in Lungs. Tissue 
Barriers 6(4): 1-13. 
22. Karbalaei M, Ghazvini K, Keikha M (2020) Clinical efficacy of vitamin 
D supplementation on pulmonary TB patients: The evidence of clinical 
trials. J Clin Tuberc Other Mycobact Dis 20: 100174. 
Copyright@ Walter Manucha | Biomed J Sci & Tech Res | BJSTR. MS.ID.006314.
Volume 39- Issue 3 DOI: 10.26717/BJSTR.2021.39.006314
31424
23. Wang H, Chen W, Li D, Yin X, Zhang X, et al. (2017) Vitamin D and Chronic 
Diseases. Aging Dis 8(3): 346-353. 
24. Charoenngam N, Holick MF (2020) Immunologic Effects of Vitamin D on 
Human Health and Disease. Nutrients 12(7): 2097. 
25. Djukic M, Onken ML, Schütze S, Redlich S, Götz A, et al. (2014) Vitamin 
d deficiency reduces the immune response, phagocytosis rate, and 
intracellular killing rate of microglial cells. Infect Immun 82(6): 2585-
2594.
26. Chung C, Silwal P, Kim I, Modlin RL, Jo EK (2020) Vitamin D-Cathelicidin 
Axis: at the Crossroads between Protective Immunity and Pathological 
Inflammation during Infection. Immune Netw 20(2): e12.
27. Youssef DA, Miller CW, El Abbassi AM, Cutchins DC, Cutchins C, et al. 
(2011) Antimicrobial implications of vitamin D. Dermatoendocrinol 
3(4): 220-229. 
28. Ahmed A, Siman Tov G, Hall G, Bhalla N, Narayanan A (2019) Human 
Antimicrobial Peptides as Therapeutics for Viral Infections. Viruses 
11(8): 704.
29. Germic N, Frangez Z, Yousefi S, Simon HU (2019) Regulation of the innate 
immune system by autophagy: neutrophils, eosinophils, mast cells, NK 
cells. Cell Death Differ 26(4): 703-714. 
30. Shojaei S, Suresh M, Klionsky DJ, Labouta HI, Ghavami S (2020) 
Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the 
autophagy pathway. Virulence 11(1): 805-810.
31. Gassen NC, Niemeyer D, Muth D, Corman VM, Martinelli S, et al. (2019) 
SKP2 attenuates autophagy through Beclin1-ubiquitination and its 
inhibition reduces MERS-Coronavirus infection. Nat Commun 10(1): 
5770. 
32. Berridge MJ (2017) Vitamin D deficiency accelerates ageing and age-
related diseases: a novel hypothesis. J Physiol 595(22): 6825-6836. 
33. Rolf L, Muris AH, Hupperts R, Damoiseaux J (2014) Vitamin D effects on 
B cell function in autoimmunity. Ann N Y Acad Sci 1317: 84-91.
34. Keleş E, Özkara Ş, İlhan N, Güngör H, Karlıdağ T, et al. (2015) The 
Relationship between Th1/Th2 Balance and 1α, 25-Dihydroxyvitamin 
D3 in Patients with Allergic Rhinitis. Turk Arch Otorhinolaryngol 53(4): 
139-143.
35. Schrumpf JA, Van der Does AM, Hiemstra PS (2020) Impact of the Local 
Inflammatory Environment on Mucosal Vitamin D Metabolism and 
Signaling in Chronic Inflammatory Lung Diseases. Front Immunol 11: 
1433. 
36. Tsujino I, Ushikoshi Nakayama R, Yamazaki T, Matsumoto N, Saito I 
(2019) Pulmonary activation of vitamin D3 and preventive effect against 
interstitial pneumonia. J Clin Biochem Nutr 65(3): 245-251. 
37. Hu G, Dong T, Wang S, Jing H, Chen J (2019) Vitamin D3-vitamin D 
receptor axis suppresses pulmonary emphysema by maintaining 
alveolar macrophage homeostasis and function. EBio Medicine 45: 563-
577. 
38. Shi YY, Liu TJ, Fu JH, Xu W, Wu LL, et al. (2016) Vitamin D/VDR signaling 
attenuates lipopolysaccharide induced acute lung injury by maintaining 
the integrity of the pulmonary epithelial barrier. Mol Med Rep 13(2): 
1186-1194. 
39. Zemlin AE, Wiese OJ (2020) Coronavirus disease 2019 (COVID-19) and 
the renin-angiotensin system: A closer look at angiotensin-converting 
enzyme 2 (ACE2). Ann Clin Biochem 57(5): 339-350.
40. Wiese OJ, Allwood BW, Zemlin AE (2020) COVID-19 and the renin-
angiotensin system (RAS): A spark that sets the forest alight? Med 
Hypotheses 144: 110231.
41. Li G, He X, Zhang L, Ran Q, Wang J, et al. (2020) Assessing ACE2 
expression patterns in lung tissues in the pathogenesis of COVID-19. J 
Autoimmun 112: 102463. 
42. Verdecchia P, Cavallini C, Spanevello A, Angeli F (2020) The pivotal link 
between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med 
76: 14-20. 
43. Zhang X, Li S, Niu S (2020) ACE2 and COVID-19 and the resulting ARDS. 
Postgrad Med J 96(1137): 403-407. 
44. Abou Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L (2020) The 
hypercoagulable state in COVID-19: Incidence, pathophysiology, and 
management. Thromb Res 194: 101-115.
45. Becker RC (2020) COVID-19 update: Covid-19-associated coagulopathy. 
J Thromb Thrombolysis 50(1): 54-67. 
46. Rai DK, Kumar S, Sahay N (2021) Post-COVID-19 pulmonary fibrosis: A 
case series and review of literature. J Family Med Prim Care 10(5): 2028-
2031.
47. Rai DK, Sharma P, Kumar R (2021) Post covid 19 pulmonary fibrosis. Is it 
real threat? Indian J Tuberc 68(3): 330-333.
48. Dancer RC, Parekh D, Lax S, D’Souza V, Zheng S, et al. (2015) Vitamin 
D deficiency contributes directly to the acute respiratory distress 
syndrome (ARDS). Thorax 70(7): 617-624. 
49. Xu J, Yang J, Chen J, Luo Q, Zhang Q, et al. (2017) Vitamin D alleviates 
lipopolysaccharide induced acute lung injury via regulation of the renin 
angiotensin system. Mol Med Rep 16(5): 7432-7438. 
50. Lo KB, McCullough PA, Rangaswami J (2020) Antihypertensive drugs 
and risk of COVID-19? Lancet Respir Med 8(5): e29. 
51. Semenzato L, Botton J, Drouin J, Baricault B, Vabre C, et al. (2021) 
Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 million 
Hypertensive Patients. Hypertension 77(3): 833-842.
Copyright@ Walter Manucha | Biomed J Sci & Tech Res | BJSTR. MS.ID.006314.
Volume 39- Issue 3 DOI: 10.26717/BJSTR.2021.39.006314
31425
Submission Link: https://biomedres.us/submit-manuscript.php
Assets of Publishing with us
• Global archiving of articles
• Immediate, unrestricted online access
• Rigorous Peer Review Process
• Authors Retain Copyrights
• Unique DOI for all articles
https://biomedres.us/
This work is licensed under Creative
Commons Attribution 4.0 License
ISSN: 2574-1241
DOI: 10.26717/BJSTR.2021.39.006314
Walter Manucha. Biomed J Sci & Tech Res
